Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

2 terminated/withdrawn out of 18 trials

Success Rate

84.6%

-1.9% vs industry average

Late-Stage Pipeline

17%

3 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
10(71.4%)
Phase 3
2(14.3%)
Phase 4
1(7.1%)
Phase 2
1(7.1%)
14Total
Phase 1(10)
Phase 3(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT03817502Phase 3Recruiting

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Role: lead

NCT06186271Recruiting

International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)

Role: collaborator

NCT06028555Recruiting

International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study

Role: collaborator

NCT06990204Phase 1Not Yet Recruiting

Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)

Role: lead

NCT06823856Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Role: lead

NCT06766500Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Role: lead

NCT06792968Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Role: lead

NCT05087030Phase 3Completed

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

Role: lead

NCT05738850Phase 1Completed

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Role: collaborator

NCT05322096Phase 2Completed

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

Role: lead

NCT04306692Phase 4Terminated

Myo-inositol Versus Clomiphene Citrate in PCOS

Role: collaborator

NCT02577913Terminated

European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception

Role: collaborator

NCT03349190Completed

Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques

Role: collaborator

NCT03146988Phase 1Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Role: lead

NCT02165098Phase 1Completed

Cariprazine: Comparison of Slow- and Immediate-release Forms

Role: lead

NCT02223416Phase 1Completed

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

Role: lead

NCT02371096Phase 1Unknown

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Role: lead

NCT02001584Phase 1Completed

A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults

Role: lead

All 18 trials loaded